Adverse Outcomes in Pulmonary Tuberculosis patients on Retreatment Regimen: Evaluation of Pharmacokinetic Estimates as Risk Indicators

Author:

Mohan Anant,Bhatnagar Anuj,Gupta Tarang,Kanswal Sunita,Das Ujjalkumar,Velpandian Thirumurthy,Guleria Randeep,Singh Urvashi B.

Abstract

AbstractPatients with pulmonary tuberculosis (PTB) who fail therapy or develop a relapse are initiated on re-treatment regimen. These patients are known to have adverse outcomes. This study aimed to determine the role of plasma levels of Anti-tubercular drugs in treatment outcome. Plasma levels of retreatment regimen drugs [Isoniazid(INH), Rifampicin(RIF), Pyrazinamide(PZA), Ethambutol(EMB), and Streptomycin(STM)] were compared between treatment responsive/cured and treatment failure/not-cured patients. Plasma drug levels were analysed by LC-MS/MS at different time points in 134 PTB patients on retreatment regimen. Of the 134 subjects, 108 were cured, 17 patients developed multi-drug resistant TB (MDR-TB), and 9 patients remained smear positive at treatment completion (8 months). The two-hour plasma levels (C2hr) (geometric mean) were lower in ‘Not Cured’ subjects compared to ‘Cured’ subjects Notably, in the 26 ‘Not Cured’ subjects, C2hr plasma levels after first dose at Day0 were significantly low (INH: 0.86 vs 2.94 µg/ml p≤0.002, RIF: 0.56 vs 2.55 µg/ml p≤0.003, PZA: 1.85 vs 26.58 µg/ml p≤0.000 and EMB: 0.72 vs 1.53 µg/ml p≤0.010). In contrast, STM levels were higher (31.84 vs 18.08 µg/ml p ≤0.007). Based on ROC analysis of the data, therapeutic indicator values for successful treatment outcome were C2hr plasma levels of 10.6 µg/ml for PZA, 1.14 µg/ml for RIF, 1.86 µg/ml for INH and 1.24 µg/ml for EMB. Therapeutic failure in PTB patients on retreatment regimen is associated with lower plasma drug levels. Therapeutic drug monitoring would prove useful to maintain drug levels above the minimum cut-off levels for obtaining favourable clinical outcome.

Publisher

Cold Spring Harbor Laboratory

Reference33 articles.

1. WHO. 2013; updated Dec 2014 and Jan 2020. Definitions and reporting framework for tuberculosis—2013 revision. World Health Organisation Switzerland, Geneva.

2. WHO. 2010 (updated 2017). Treatment of Tuberculosis Guidelines,4th edition Organisation WH, Geneva, Switzerland.

3. Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study;PLoS Med,2011

4. Cohen DB , Davies G , Malwafu W , Mangochi H , Joekes E , Greenwood S , Corbett L , Squire SB . 2019. Poor outcomes in recurrent tuberculosis: More than just drug resistance? PLoS One 14.

5. Source of retreatment cases under the revised national TB control programme in Rajasthan, India, 2003;Int J Tuberc Lung Dis,2006

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3